Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States. The company provides nanoforming technologies, formulation, and analytical services, including controlled expansion of supercritical solutions technology that enables the creation of active pharmaceutical ingredients (API) nanoparticles directly from solution; biological nanoforming technology; and dosage forms of Nanoparticles. It also offers STARMAP, an AI platform predicts the performance of your molecule in Nanoform's technology. The company was founded in 2008 and is headquartered in Helsinki, Finland.
Frequently asked questions
What sector does Nanoform Finland Plc (NANOFH) operate in?
Nanoform Finland Plc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Nanoform Finland Plc (NANOFH) current stock price?
As of the latest data, Nanoform Finland Plc stock price is €0.70, with a previous close of €0.68. Nanoform Finland Plc gained €0.02 in the last trading session, representing a 2.65% increase.
What is Nanoform Finland Plc (NANOFH) current market capitalization?
Nanoform Finland Plc market cap is approximately 59.86 million.
What is Nanoform Finland Plc (NANOFH) Earnings Per Share (EPS)?
The trailing EPS is -€0.16, and the forward EPS is -€0.11.
What is Nanoform Finland Plc (NANOFH) EBITDA?
Nanoform Finland Plc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.79 million.
Does Nanoform Finland Plc (NANOFH) pay dividends?
No. Nanoform Finland Plc does not pay a dividend.
When is Nanoform Finland Plc (NANOFH) next earnings report?
Nanoform Finland Plc is expected to release its next earnings report on September 30, 2026.
What is Nanoform Finland Plc (NANOFH) beta (volatility) score?
Nanoform Finland Plc has a beta of 0.876, meaning its volatility is roughly in line with the market.
